Breast cancer is one of the most common type of solid cancer with incidence rate 16.7% of all cancer cases in Indonesia. There are several molecular subtypes in breast cancer. Among these molecular subtypes, basal-like breast cancer, commonly known as triple-negative breast cancer, has a more aggressive clinical course than other subtypes. Most of previous studies showed that triple negative breast cancer showed worse prognosis compared to hormonal positive breast cancer. Triple negative breast cancer has a higher number of tumor infiltrating lymphocytes and Programmed Death-Ligand 1 expression compared to other subtypes. Before the era of immunotherapy, triple negative breast cancer patients were treated using chemotherapy either as neoadjuvant or adjuvant chemotherapy. However, treatment of metastatic triple negative breast cancer using chemotherapy has limited effectiveness and also associated with unexpected toxicity profile. Therefore, other therapeutic agent options to improve the outcomes of treatment in triple negative breast cancer were developed. New treatments in triple negative breast cancer have different target of pathways or molecules. Immunotherapy, based on specific biomarkers, is a new hope in the management of triple negative breast cancer.
Key words: triple negative breast cancer, treatment, immunotherapy
|
